WO1997034869A1 - Derives de l'acide carboxylique a cycles fusionnes - Google Patents
Derives de l'acide carboxylique a cycles fusionnes Download PDFInfo
- Publication number
- WO1997034869A1 WO1997034869A1 PCT/JP1997/000852 JP9700852W WO9734869A1 WO 1997034869 A1 WO1997034869 A1 WO 1997034869A1 JP 9700852 W JP9700852 W JP 9700852W WO 9734869 A1 WO9734869 A1 WO 9734869A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- substituent
- ring
- optionally
- substituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/337—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
- C07C69/94—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of polycyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Definitions
- the present invention relates to a fused ring-containing carboxylic acid derivative and a pharmacologically acceptable salt thereof. More specifically, the present invention relates to a novel fused ring-containing carboxylic acid derivative having a retinoic acid resebutagonist action, and a pharmaceutically acceptable salt thereof.
- Retinoic acid is an essential substance for the growth and survival of humans and mammals. It is known that it has a wide variety of effects on the differentiation and proliferation of cells during morphogenesis during adult development and also in adults. For example, it is involved in the keratinization reaction, hair formation and sebaceous gland function in the epidermis, bone and cartilage metabolism in connective tissue, immune function regulation in the immune system, differentiation of nerve cells in the nervous system, and blood cell differentiation in the blood system. It is known to be involved in differentiation, proliferation, other lipid metabolism, mineral metabolism and basal metabolism.
- retinoic acids The various physiological actions of these retinoic acids are controlled by the expression of transcriptional activators through retinoid receptor family present in the nucleus of cells, enzymes such as collagenase, tissue plasminogen activator ⁇ tyrosine kinase, etc. In addition, it is exerted by various control mechanisms such as regulation of production of cytokines such as IL-16.
- X is a group represented by the formula —O—, a group represented by the formula —S—, or
- R 1 may be a hydrogen atom, a halogen atom, or a substituent
- Y is a group represented by the formula —O—, a group represented by the formula —S—, or
- R 2 is a hydrogen atom, a halogen atom, a lower alkyl group which may have a substituent, a cycloalkyl group which may have a substituent, or an aryl which may have a substituent.
- heteroaryl group optionally having substituent (s), lower alkoxy group optionally having substituent (s), aryloxy group optionally having substituent (s), optionally having substituent (s) Good heteroaryloxy group, cycloalkylalkyl group optionally having substituent (s), arylalkyl group optionally having substituent (s) Heteroarylalkyl group optionally having substituent (s), substitution With group A cycloalkyloxy group which may be substituted, an alkylalkyloxy group which may have a substituent, an arylalkyloxy group which may have a substituent, and a substituent Or an alkenyl group which may have a substituent or an alkynyl group which may have a substituent. ) Means a group represented by. y means an integer of 0 or 1.
- Z represents a group represented by the formula O—, a group represented by the formula S—, or
- R 3 is a hydrogen atom, a halogen atom, a lower alkyl group which may have a substituent, a cycloalkyl group which may have a substituent, or an aryl which may have a substituent.
- a heteroaryl group which may have a substituent a lower alkoxy group which may have a substituent, an aryloxy group which may have a substituent, and a substituent
- z represents an integer of 0 or 1.
- P is a group represented by the formula 10—, a group represented by the formula S—, or R 4
- R 4 is a hydrogen atom, a halogen atom, a lower alkyl group which may have a substituent, a cycloalkyl group which may have a substituent, or an aryl which may have a substituent.
- a heteroaryl group which may have a substituent a lower alkoxy group which may have a substituent, an aryloxy group which may have a substituent, and a group which has a substituent Heteroaryloxy group, cycloalkylalkyl group optionally having substituent (s), arylalkyl group optionally having substituent (s), heteroarylalkyl group optionally having substituent (s)
- a group, a cycloalkyloxy group which may have a substituent, an alkylalkyloxy group which may have a substituent, an arylalkyloxy group which may have a substituent May have a substituent
- To Teroa Li one Ruarukiruokishi group, an optionally substituted alkenyl group, or means a group represented by that.) Refers to an alkynyl group which may have a substituent. p represents an integer of 0 or 1.
- Q is a group represented by the formula O—, a group represented by the formula S—, or
- R 3 is a hydrogen atom, a halogen atom, a lower alkyl group which may have a substituent, a cycloalkyl group which may have a substituent, or a group which may have a substituent.
- U is a group represented by the formula —O—, a group represented by the formula —S—, or
- R 6 is a hydrogen atom, a halogen atom, a lower alkyl group which may have a substituent, a cycloalkyl group which may have a substituent, or a group which may have a substituent.
- Teraryl alkyl group optionally substituted alkyloxy group, optionally substituted alkylalkyloxy group, optionally substituted alkylalkyl group Even if it has a xy group or a substituent
- Good heterosexual It means a rualkyloxy group, an alkenyl group which may have a substituent or an alkynyl group which may have a substituent.
- V is a group represented by the formula —O—, a group represented by the formula —S—, or
- R 7 may be a hydrogen atom, a halogen atom, a substituted or unsubstituted lower alkyl group, a substituted or unsubstituted cycloalkyl group, or a substituted group.
- Aryl group a heteroaryl group which may have a substituent, a lower alkoxy group which may have a substituent, an aryloxy group which may have a substituent, and a substituent
- Optionally substituted heteroaryloxy group optionally substituted cycloalkylalkyl group, optionally substituted arylalkyl group, optionally substituted Heteroarylalkyl group, optionally substituted alkyloxy group, optionally substituted alkylalkyloxy group, arylalkyl optionally having substituent (s) Even if it has an alkoxy group or a substituent Tekoa Lee Ruarukiruokishi group to have, which may have a substituent alkenyl group, an alkynyl group which may have a location substituent, or
- Ring A and ring B independently represent an aromatic hydrocarbon ring or an unsaturated heterocyclic ring which may have a substituent, and D is a carboxyl group which may have a protecting group.
- Means a group represented by V represents an integer of 0 or 1.
- W is a group represented by formula O—, a group represented by formula S—, or
- R 8 may be a hydrogen atom, a halogen atom, a substituted or unsubstituted lower alkyl group, a substituted or unsubstituted cycloalkyl group, or a substituted group.
- a ring and B ⁇ ⁇ ⁇ independently represent an aromatic hydrocarbon ring or an unsaturated heterocyclic ring which may have a substituent, and D means a carboxyl group which may have a protecting group.
- w means an integer of 0 or 1:
- R ⁇ , R 2 , R 3 , R 4 , R 5 , R 6 , R T and R 8 are taken together and together with the carbon atom to which they are attached.
- This ring may contain a heteroatom and may have a substituent.
- V and W is the formula (R K 'means R 7 or R s ), and R 7 or R s is the formula (A ⁇ and B rings independently represent an aromatic hydrocarbon which may have a substituent or an unsaturated heterocycle, and D is a carboxyl group which may have a protecting group. -) 3 Excluding compounds where L ⁇ is completely saturated. ⁇
- the present invention provides a pharmacologically effective amount of the above fused ring-containing carboxylic acid.
- a pharmaceutical composition comprising an acid derivative, a pharmacologically acceptable salt thereof, or a hydrate thereof, and a pharmacologically acceptable carrier.
- the present invention provides a retinoic acid receptor agonist which is a carboxylic acid derivative having a condensed ring or a pharmaceutically acceptable salt thereof or a hydrate thereof.
- the present invention is also a prophylactic / therapeutic agent for diseases in which the agonist action of retinoic acid receptor is effective.
- the present invention relates to a method for producing a pharmacologically effective amount of the above-mentioned condensed ring-containing carboxylic acid derivative or a pharmacologically acceptable salt thereof or a hydrate thereof so that the retinoic acid receptor agonizing effect is effective.
- the halogen atom in the definition of R 1 R 2 , R 3 , R ⁇ R 5 , R ⁇ R 7 and R s is a fluorine atom, a chlorine atom, a bromine atom, It means iodine atom and the like.
- the lower alkyl group found in the definitions of RR 2 , R 3 , R ⁇ RR 6 , R 7 and R 8 means a straight-chain or branched alkyl group having 1 to 6 carbon atoms.
- these alkyl groups may be substituted by 13 halogen atoms such as a fluorine atom, a chlorine atom, a bromine atom and an iodine atom. That is, a trifluoromethyl group, a dibromoethyl group and the like are also included in the straight-chain or branched lower alkyl group in the general formula (A).
- RRR 3 and the R 4, R 5, R 6 consequent Roanorekiru groups found in the definitions of R 7 and R 8, consequent Ropuro propyl group, cyclobutyl group, consequent opening Benchiru group, hexyl group consequent Russia, the consequent b It means those having 1 to 8 carbon atoms such as butyl group or cyclooctyl group.
- Examples include methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, sec-butoxy, tert-butoxy, n-pentyloxy, 1,2 —Dimethylpropyloxy, 1,1-dimethylpropyloxy, 2,2-dimethylpropyloxy, 2-ethylpropyloxy, n-hexyloxy, 1,2-dimethylbutyloxy, 2,3-dimethyl
- Examples thereof include a butoxy group, a 1,3-dimethylbutyloxy group, a 1-ethylenol 2-methynolepropynoleoxy group, and a 1-methynole-12-ethylbutylcopyroxy group.
- alkenyl groups contain 13 fluorine atoms, chlorine atoms, bromine atoms, iodine atoms, etc. May be substituted with a halogen atom. That is, a trifluoromethoxy group, a dibucomethoxy group, and the like are also included in the lower alkoxy group in the present invention.
- R ′, R 2 , R 3 , R 4 , R 5 , R e , R 7 and R 8 may have a substituent, and the aryl may be a phenyl group; 1 Means a naphthyl group, 2-naphthyl group or anthracenyl group.
- the aromatic hydrocarbon ring which may have a substituent as defined in the definition of the ring A and the ring B, the aromatic hydrocarbon ring means a benzene ring, a naphthalene ring, an anthracenyl ring and the like:
- a heteroaryl group which may have a substituent as defined in the definitions of RR 2 , R 3 , R 4 , R s , R 6 , R 7 and R 8 is a sulfur atom, an oxygen atom or a nitrogen atom.
- 1 to 4 means a group derived from a single or fused ring.
- hetero ⁇ refers to a single or fused ring containing 114 sulfur, oxygen or nitrogen atoms.
- aryl is the same as the above aryl group. Meaningful.
- the alkyl in this case has the same meaning as the lower alkyl.
- RRR 3, and R ⁇ R 5, R 6, R 7 and heteroarylalkyl group to a good substituted seen in the definition of R 8 are both Tekoa Li Lumpur is the lower alkyl to the 3 which means that which it is joined to the Kano carbon atoms
- an aryl group which may have a substituent a heteroaryl group which may have a substituent, an arylalkyl group which may have a substituent, and which may have a substituent
- the substituent means a straight-chain or branched lower alkyl group such as methyl, ethyl, n-propyl, or isopropyl, methoxy, ethoxy, n-bromoboxy, isopropoxy, etc.
- a straight-chain or branched lower alkoxy group such as a fluorine atom, a chlorine atom, a bromine atom and an iodine atom, an aryl group which may have a substituent, and a substituent Heteroaryl group, arylalkyl group optionally having substituent (s), heteroarylalkyl group optionally having substituent (s), halogen atom, hydroxyl group, hydroxyalkyl group, It means an alkoxyalkyl group and the like.
- the protecting group is, for example, a lower alkyl group such as a methyl group, an ethyl group, a t-butyl group, P-methoxybenzinole, p- Nitrobenzyl, 3,4-dimethoxybenzyl, diphenyl / remethyl, trityl, phenyl, a lower alkyl group substituted with an optionally substituted phenyl group, 2,2,2-to- Norogenated lower alkyl groups such as chloroethynole, 2-hydroxyethyl, bivaloyloxymethyl, acetoxymethyl, popionyloxymethyl, butyryloxymethyl, valeryloxymethyl, 1-acetoxicetyl, 2 — Lower alkanoyloxy lower alk, such as acetoxityl, 1-pivaloy oleoxycetinole, and 2 Group, Palmi Toiruokishe
- Lower alkyl (substituted dioxolen) such as methyl, cycloalkyl-substituted lower alkyl such as 1-cyclohexylacetyloxoshetyl
- alkanoyloxy lower alkyl groups cycloalkyloxycarbonyloxy lower alkyl groups such as 1-cyclohexyloxycarbonyloxyshetyl, and amino groups which may have a substituent.
- the carboxyl group which may have a protecting group is a hydroxyl group or a group which is decomposed by a chemical means or in vivo to give a carboxylic acid.
- the pharmacologically acceptable salt in the present invention includes, for example, inorganic salts such as hydrochloride, hydrobromide, sulfate, and phosphate, for example, acetate, maleate, tartrate, and methanesulfonic acid.
- inorganic salts such as hydrochloride, hydrobromide, sulfate, and phosphate
- examples thereof include salts, organic salts such as benzenesulfonate and toluenesulfonate, and salts with amino acids such as aspartic acid and glutamic acid.
- optical isomers are present in these compounds, they are also included in the present invention.
- the compounds of the present invention can be easily obtained by commonly used methods or by combining commonly used methods. An example is shown below.
- organometallic reagent examples include a Grignard reagent, an organic lithium reagent, an organic zinc reagent, and an organic copper complex.
- reaction solvent examples include a force that can use anything that does not participate in the reaction; ethers such as ether and tetrahydrofuran; and the like. Reaction temperatures range from about 178 ° C to the boiling point of the solvent, but preferably from about 178 ° C to 20 ° C.
- the aryl alcohol compound (2) obtained in step 1 is oxidized by a usual method to obtain a vinyl ketone compound (3).
- the oxidation may be carried out by any method that is commonly used, Oxidation using an appropriate oxidizing agent is preferred.
- the oxidizing agent activated manganese dioxide, pyridinium chromate, pyridinium dichromate, Dess-Martin reagent, Swern oxidation and the like are used.
- the reaction solvent any organic solvent that does not participate in the reaction can be used; dichloromethane, culoform form, acetone, and the like can be mentioned as preferred ones.
- the reaction temperature is a force S, which is from about 178 ° C to the boiling point of the solvent, preferably from about 178 ° C to 20 ° C.
- the diketone compound represented by the general formula (5) is obtained by the method of Stetter 5 described in Org. Synth. 65, 26. Is a way to get
- reaction solvent methanol, ethanol, N, N-dimethylformamide and the like are used.
- reaction temperature is preferably from about 60 C to the boiling point of the solvent.
- the diketone compound (5) obtained in the step 3 is treated by a commonly used method to obtain a pyrrole compound represented by the general formula (6).
- the target compound (6) can be obtained by reacting with an ammonium salt such as ammonium acetate or a primary amine.
- an alcohol-based solvent such as methanol or ethanol, acetic acid, or the like is used as a reaction solvent.
- the reaction temperature is preferably from about 70 ° C to the boiling point of the solvent.
- the final target compound represented by the general formula (7) can be obtained by hydrolyzing the pyrrole compound (6) obtained in the step 4 in a usual manner:
- a base is used
- An aqueous solution of lithium hydroxide, sodium hydroxide, potassium hydroxide, etc. gives good results as the base.
- Methanol Preference is given to alcohol solvents such as ethanol or ether solvents such as tetrahydrofuran, etc.
- the reaction temperature is preferably from about 20 ° C. to the boiling point of the solvent.
- the human RAR and y genes were introduced into BHK (Baby Hamstar Kidney) cells to create cells that constantly express RAR a , ⁇ , and ⁇ proteins.
- BHK Baby Hamstar Kidney
- the inhibition rate of binding is measured and the ability of the compound to bind to RAR is determined.
- the selectivity of each compound for RAR was determined by comparing the binding ability of a single receptor.
- RAR gene B HK 5 x 10 8 cells in 15 ml of solution A (5 mM sodium phosphate (pH 7.4), 10 mM monothioglycerol, 10 ⁇ / ⁇ (v / v) was suspended in 1 mM phenylmethylinolesulfonyl fluoride (PMSF), 10 ug / ml aprotinin, and 25 g / ml leptin), homogenized, and centrifuged to remove the supernatant.
- PMSF phenylmethylinolesulfonyl fluoride
- solution B (lOraM Tris-HCl (pH 8.5), lOmM monothioglycerol, 10% (v / v) glycerol, 1 mM PMSF, 10 ⁇ g / ml abrotinin, 25 g / ml leptin, 0.4 M chloride Suspension at 4 ° C for 1 hour, and then ultracentrifuged at 100,000 X g at 4 ° C for 1 hour.
- solution B lOraM Tris-HCl (pH 8.5), lOmM monothioglycerol, 10% (v / v) glycerol, 1 mM PMSF, 10 ⁇ g / ml abrotinin, 25 g / ml leptin, 0.4 M chloride Suspension at 4 ° C for 1 hour, and then ultracentrifuged at 100,000 X g at 4 ° C for 1 hour.
- the obtained supernatant was used as a nuclear extract fraction and stored frozen at -80 ° C until use.
- a human RAR expression vector and a secretory alkaline phosphatase (PLAP) gene vector (PLAP vector) containing a response element that binds to the RAR and suppresses expression in a ligand-dependent manner are incorporated upstream.
- PLAP vector secretory alkaline phosphatase gene vector
- COS-1 Africann midris monkey-derived kidney cell line
- PLAP produced in a ligand-dependent manner and secreted into the culture medium is measured using a chemiluminescence method. By doing so, the transcription promoting activity of the compound was examined. In addition, by comparing the transcription promoting ability of each receptor, the selection system for RAR of each compound was determined.
- the recovered samples were treated for 10 minutes at 65 ° C to remove non-specific activity-15 ⁇ l of the sample was mixed with 60 ⁇ l of 28 ⁇ sodium carbonate buffer ( ⁇ ) and the chemiluminescent substrate smileite ( (Trademark; manufactured by Sumitomo Metals Co., Ltd.) 1 was added and reacted at 37 C for 30 minutes, and the luminescence was measured.
- the following compounds induced the RAR transcription activity in a concentration-dependent manner
- the condensed ⁇ -containing carboxylic acid derivative represented by the general formula (A) or a pharmacologically acceptable salt thereof has a retinoic acid receptor-agonist action. It became. Therefore, the compounds of the present invention are useful as agents for preventing or treating diseases for which retinoic acid receptor agonist action is effective.
- Alopecia areata, seborrheic alopecia, cachectic alopecia and other alopecia; postmenopausal osteoporosis, senile osteoporosis, steroid osteoporosis, idiopathic osteoporosis, diabetic bone Various osteoporosis and osteopenia such as osteopenia, rheumatoid arthritis osteopenia, and renal osteomalacia; bone and joint diseases such as ectopic hyperostosis, osteoarthritis, and shoulder periarthritis Rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, Behcet's disease, mycosis fungoides, systemic scleroderma, idiopathic thrombocytopenic purpura, myas
- the administration route is appropriately selected. It may be administered orally as tablets, powders, granules, capsules, syrups, etc., or parenterally as suppositories, injections, external preparations, infusions, etc. You may.
- the dosage varies significantly depending on the type of disease, the degree of symptoms, the period from onset to the first administration, the age of the patient, gender difference, sensitivity difference, etc., usually about 0.03 per day as an adult. 1 to 1000 mg, preferably 0.1 to 500 mg, and more preferably 0.1 to 100 rag, in 1 S 1 to several doses.
- Formulation of the compound of the present invention can be carried out by a conventional method using a usual carrier for preparation.
- tablets when preparing an oral solid dosage form, after adding excipients, binders, disintegrants, lubricants, coloring agents, flavoring agents, antioxidants, etc. of the main drug, tablets are prepared in the usual manner. , Coated tablets, granules, powders, capsules, etc.
- excipient for example, lactose, corn starch, sucrose, sucrose, sorbite, crystalline cellulose, silicon dioxide and the like are used.
- binder examples include polyvinyl alcohol, polyvinyl alcohol, ethanol, ethanol, ethanol, ethanol, gum arabic, gelatin, ceramics, hydroxypropyl cellulose, and hydroxypropyl cellulose.
- Hydroxib mouth Pinoremeth / resenololose, canolesum citrate, dextrin, pectin, etc. are used.
- Magnesium phosphate, talc, polyethylene glycol, silica, hydrogenated vegetable oil, etc. are used.
- Any coloring agent that is permitted to be added to pharmaceuticals may be used, and as a flavoring agent, cocoa powder, heart-shaped brain, aromatic acid, heart-shaped oil, dragon brain, For example, cinnamon powder is used.
- the main drug when manufacturing injections, should contain ⁇ adjusters, buffers, suspending agents, solubilizers, stabilizers, isotonic agents, antioxidants, preservatives, etc. as necessary. It can be added and manufactured by a conventional method. At this time, if necessary, it can be a freeze-dried product.
- the injection can be administered intravenously, subcutaneously, or intramuscularly.
- suspending agents examples include, for example, methylcellulose, polysonolate 80, hydroxyxetinoresenorelose, arabic gum, tragacanth powder, and carboxymethylcellulose nato.
- Lithium, polyoxyethylene sorbitan monolaurate and the like can be mentioned.
- solubilizers include polyoxyethylene hydrogenated castor oil, polysorbate 80, nicotinic acid amide, and polyoxyethylene sorbitan monolaurate.
- the title compound was obtained as an oily substance using 5,7-dimethyl-1-tetralone in the same manner as in Production Example 1.
- the mixture was extracted with ethyl acetate (100 ml ⁇ 2), and the organic layers were combined, washed with water, a saturated aqueous solution of sodium hydrogen carbonate and saturated saline in this order, and dried over anhydrous magnesium sulfate. After filtration, the filtrate was concentrated to obtain 1.5 g of an alcohol.
- the title compound was obtained from 2-cyano-8-ethylnaphthalene in the same manner as in Production Example 4.
- the title compound was obtained as an oily substance from 2-cyano-8-isobrodinylnaphthalene in the same manner as in Production Example 4.
- the title compound was obtained as a colorless solid in the same manner as in (A) of Production Example 29 using 3-ethyl 4-fluoroacetic acid.
- the title compound was obtained as a colorless oil in the same manner as in (A) and (B) using 4-ethyl-5-fluoro-2-methoxybenzaldehyde.
- the title compound was obtained as a colorless oily substance in the same manner as in Production Example 29 (C) using 2,5-getyl-4-fluorofluorosol.
- the title compound was obtained in the same manner as in Production Example 27 using 3-ethyl-4-fluoroazole.
- 2,5—Difluorophenylethanol ether I3g was dissolved in N, N-dimethylaniline 90ml and stirred under nitrogen stream at 170 ° C for 5 hours: The reaction solution was poured into 10% aqueous hydrogen chloride solution and acetic acid Extracted with ethyl. The organic layer was washed with saturated saline, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The resulting residue was subjected to silica gel chromatography (developing solvent; 7% ethyl acetate n-hexane). This gave 7.8 g of the title compound as a colorless oil. l H-R (CDCl 3, 400MHz) ⁇ ;
- Example 1 (B) was obtained in the same manner as Method 1 ( l H-NMR (CDCl 3, 400 MHz) ⁇ ;
- Example 1 (B) was obtained in the same manner as in Method 2.
- Example 1 (B) was obtained in the same manner as in method 2, 'H-NMRCCDCl 3, 400 MHz) ⁇ ;
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU19423/97A AU723930B2 (en) | 1996-03-18 | 1997-03-18 | Fused-ring carboxylic acid derivatives |
EP97907344A EP0889032A4 (en) | 1996-03-18 | 1997-03-18 | CARBOXYLIC ACID DERIVATIVES WITH FUSED CYCLES |
US09/125,522 US6121309A (en) | 1996-03-18 | 1997-03-18 | Fused-ring carboxylic acid derivatives |
CA002247451A CA2247451C (en) | 1996-03-18 | 1997-03-18 | Carboxylic acid derivatives having fused rings as retinoic acid receptor agonist |
JP53335197A JP3995716B2 (ja) | 1996-03-18 | 1997-03-18 | 縮合環含有カルボン酸誘導体 |
NZ331466A NZ331466A (en) | 1996-03-18 | 1997-03-18 | Fused-ring carboxylic acid derivatives |
KR10-1998-0707382A KR100485642B1 (ko) | 1996-03-18 | 1997-03-18 | 축합고리함유카르복실산유도체 |
NO19984331A NO312759B1 (no) | 1996-03-18 | 1998-09-17 | Karboksylsyrederivater med kondensert ring |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP8/88792 | 1996-03-18 | ||
JP8879296 | 1996-03-18 | ||
JP21083696 | 1996-08-09 | ||
JP8/210836 | 1996-08-09 | ||
JP8/345515 | 1996-12-25 | ||
JP34551596 | 1996-12-25 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/621,889 Division US6358995B1 (en) | 1996-03-18 | 2000-07-21 | Carboxylic acid derivatives having fused rings |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1997034869A1 true WO1997034869A1 (fr) | 1997-09-25 |
Family
ID=27305910
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1997/000852 WO1997034869A1 (fr) | 1996-03-18 | 1997-03-18 | Derives de l'acide carboxylique a cycles fusionnes |
Country Status (11)
Country | Link |
---|---|
US (3) | US6121309A (ja) |
EP (1) | EP0889032A4 (ja) |
JP (1) | JP3995716B2 (ja) |
KR (1) | KR100485642B1 (ja) |
CN (2) | CN1211361C (ja) |
AU (1) | AU723930B2 (ja) |
CA (1) | CA2247451C (ja) |
HU (1) | HUP9902645A3 (ja) |
NO (1) | NO312759B1 (ja) |
NZ (1) | NZ331466A (ja) |
WO (1) | WO1997034869A1 (ja) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH10158192A (ja) * | 1996-10-03 | 1998-06-16 | Eisai Co Ltd | 移植片対宿主疾患(gvhd)の治療および臓器移植時の移植片拒絶反応抑制のための医薬組成物 |
WO1998055454A2 (en) * | 1997-06-05 | 1998-12-10 | Takeda Chemical Industries, Ltd. | Benzofurans and benzothophenes as suppressors of neurodegeneration |
WO1999020309A1 (fr) * | 1997-10-22 | 1999-04-29 | Eisai Co., Ltd. | Agonistes de l'acide retinoique, agents preventifs et therapeutiques des nephrites |
FR2776511A1 (fr) * | 1998-03-31 | 1999-10-01 | Cird Galderma | Utilisation dans ou pour la preparation d'une composition d'au moins un inhibiteur de l'activite de l'acide retinoique |
JP2003081832A (ja) * | 2001-06-26 | 2003-03-19 | Takeda Chem Ind Ltd | レチノイド関連受容体機能調節剤 |
JP2003531180A (ja) * | 2000-04-20 | 2003-10-21 | アラーガン、インコーポレイテッド | 軟骨および骨の疾患の治療におけるレチノイド受容体拮抗薬または作用薬の使用 |
US6869959B1 (en) | 1999-04-28 | 2005-03-22 | Institute Of Medicinal Molecular Design Inc. | Heterocyclic carboxylic acid derivatives |
US7223791B2 (en) | 2001-06-26 | 2007-05-29 | Takeda Pharmaceutical Company Limited | Function regulator for retinoid relative receptor |
JP2008515985A (ja) * | 2004-10-13 | 2008-05-15 | ピーティーシー セラピューティクス,インコーポレーテッド | ナンセンス抑制の化合物とその使用方法 |
JP2012524715A (ja) * | 2009-04-02 | 2012-10-18 | メルク セローノ ソシエテ アノニム | ジヒドロオロテート脱水素酵素阻害剤 |
KR20170097125A (ko) * | 2014-12-17 | 2017-08-25 | 킹즈 컬리지 런던 | 레티노산 수용체 베타 (RARβ) 작동제로서 바이사이클로헤테로아릴-헤테로아릴-벤조산 화합물 |
JP2019522650A (ja) * | 2016-06-22 | 2019-08-15 | キングス カレッジ ロンドン | 4−(5−(4,7−ジメチルベンゾフラン−2−イル)−1,2,4−オキサジアゾール−3−イル)安息香酸の結晶形態及びそれらの調製方法 |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2001245401A1 (en) | 2000-03-01 | 2001-09-12 | Sumitomo Pharmaceuticals Company, Limited | Hydrazones and analogs as cholesterol lowering agents |
WO2003062230A1 (en) * | 2002-01-21 | 2003-07-31 | Eisai Co., Ltd. | Conbinatorial library of heterocycle compounds |
WO2004037843A2 (en) * | 2002-10-25 | 2004-05-06 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Steroid compounds comprising superoxide dismutase mimic groups and nitric oxide donor groups, and their use in the preparation of medicaments |
WO2004050084A2 (en) * | 2002-11-29 | 2004-06-17 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Ace-inhibitors having antioxidant and nitricoxid-donor activity |
WO2008064136A2 (en) * | 2006-11-17 | 2008-05-29 | Acadia Pharmaceuticals Inc. | Compounds with activity at retinoic acid receptors |
US9173887B2 (en) | 2010-12-22 | 2015-11-03 | Abbvie Inc. | Hepatitis C inhibitors and uses thereof |
US9630896B2 (en) | 2013-11-22 | 2017-04-25 | Tansna Therapeutics, Inc. | 2,5-dialkyl-4-H/halo/ether-phenol compounds |
WO2016161107A1 (en) | 2015-03-31 | 2016-10-06 | Syros Pharmaceuticals, Inc. | METHODS OF STRATIFYING PATIENTS FOR TREATMENT WITH RETINOIC ACID RECEPTOR-α AGONISTS |
WO2016190871A1 (en) * | 2015-05-28 | 2016-12-01 | Tansna Therapeutics, Inc. | 2,5-dialkyl-4-h/halo/ether-phenol compounds |
CN115737821B (zh) | 2016-04-08 | 2024-04-12 | 赛罗斯制药有限公司 | 用于治疗aml和mds的rara激动剂 |
US9868994B2 (en) | 2016-04-08 | 2018-01-16 | Syros Pharmaceuticals, Inc. | Methods of stratifying patients for treatment with retinoic acid receptor-α agonists |
CN109942427B (zh) * | 2019-04-17 | 2022-02-18 | 云南农业大学 | 一种单萜酚类衍生物及其合成方法和在农药中的应用 |
KR20240004737A (ko) * | 2021-05-04 | 2024-01-11 | 리젠츠 오브 더 유니버시티 오브 미네소타 | 피임 화합물 및 방법 |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS4983725A (ja) * | 1972-11-28 | 1974-08-12 | ||
JPS49112926A (ja) * | 1973-02-09 | 1974-10-28 | ||
US4129568A (en) * | 1977-05-12 | 1978-12-12 | Monsanto Company | 2-[3-Aryl-2-isoxazolin-5-yl]benzoates |
US4135910A (en) * | 1977-05-12 | 1979-01-23 | Monsanto Company | Oxadiazol-3-yl-benzoates as plant growth regulants |
US4139366A (en) * | 1977-05-12 | 1979-02-13 | Monsanto Company | 2-[5-aryl-2-isoxazolin-3-yl]benzoates and use as herbicides |
US4166732A (en) * | 1977-05-12 | 1979-09-04 | Monsanto Company | Oxadiazol-5-yl-benzoates |
JPS6185360A (ja) * | 1984-09-19 | 1986-04-30 | サントル・アンテルナシヨナル・ド・ルシエルシユ・デルマトロジツク・セ.イ.エール.デ | 複素環レチノイド |
JPH06501948A (ja) * | 1990-10-09 | 1994-03-03 | アラーガン、インコーポレイテッド | レチノイド様活性を有するクロマンおよびチオクロマン |
JPH06502178A (ja) * | 1990-12-31 | 1994-03-10 | 藤沢薬品工業株式会社 | イミダゾトリアジン誘導体 |
WO1997002244A1 (fr) * | 1995-06-30 | 1997-01-23 | Eisai Co., Ltd. | Derives d'acides carboxyliques heterocycliques et medicaments les contenant |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3743656A (en) * | 1969-05-01 | 1973-07-03 | Wyeth John & Brother Ltd | Thiophene and furan lower alkanoic acids and derivatives |
SU1051083A1 (ru) * | 1981-09-18 | 1983-10-30 | Предприятие П/Я Р-6496 | 2-(2-Карбоксифенил)-5-арилоксазолы в качестве органических люминофоров сине-фиолетового свечени в органических растворител х и водной среде и способ их получени |
US5428052A (en) * | 1984-09-19 | 1995-06-27 | Centre Internationale De Recherches Dermatologiques (C.I.R.D.) | Aromatic heterocyclic derivatives and their therapeutic and cosmetic use |
JP2752630B2 (ja) * | 1988-03-29 | 1998-05-18 | 大鵬薬品工業株式会社 | 新規安息香酸誘導体及びその製造方法 |
DE3903993A1 (de) * | 1989-02-10 | 1990-08-16 | Basf Ag | Diarylsubstituierte heterocyclische verbindungen, ihre herstellung und arzneimittel daraus |
US5162546A (en) * | 1989-09-19 | 1992-11-10 | Allergan, Inc. | Acetylenes disubstituted with a phenyl group and a 2-substituted chromanyl, thiochromanyl or 1,2,3,4-tetrahydroquinolinyl group having retinoid-like activity |
DK0638071T3 (da) * | 1992-12-28 | 1997-10-27 | Eisai Co Ltd | Heterocykliske carboxylsyrederivater, der bindes til retenoidreceptorer (RAR) |
ES2129115T3 (es) * | 1993-01-11 | 1999-06-01 | Ligand Pharm Inc | Compuestos que tienen actividad selectiva para los receptores de retinoides x, y medios para la modulacion de procesos mediados por receptores de retinoides x. |
US5474995A (en) * | 1993-06-24 | 1995-12-12 | Merck Frosst Canada, Inc. | Phenyl heterocycles as cox-2 inhibitors |
US5624957A (en) * | 1995-06-06 | 1997-04-29 | Bristol-Myers Squibb Company | Rary-specific retinobenzoic acid derivatives |
CN1090617C (zh) * | 1995-06-07 | 2002-09-11 | 日本新药株式会社 | 吡咯衍生物以及医药组合物 |
US5776699A (en) * | 1995-09-01 | 1998-07-07 | Allergan, Inc. | Method of identifying negative hormone and/or antagonist activities |
JPH0983725A (ja) | 1995-09-07 | 1997-03-28 | Sony Corp | 映像信号処理装置 |
JP2834697B2 (ja) | 1995-10-11 | 1998-12-09 | サンタニー株式会社 | ホームごたつ用脚 |
US5908858A (en) * | 1996-04-05 | 1999-06-01 | Sankyo Company, Limited | 1,2-diphenylpyrrole derivatives, their preparation and their therapeutic uses |
US5776954A (en) * | 1996-10-30 | 1998-07-07 | Merck & Co., Inc. | Substituted pyridyl pyrroles, compositions containing such compounds and methods of use |
ES2208964T3 (es) * | 1996-12-10 | 2004-06-16 | G.D. SEARLE & CO. | Compuestos de pirrolilo substituidos para el tratamiento de la inflamacion. |
US6077850A (en) * | 1997-04-21 | 2000-06-20 | G.D. Searle & Co. | Substituted benzopyran analogs for the treatment of inflammation |
-
1997
- 1997-03-18 EP EP97907344A patent/EP0889032A4/en not_active Withdrawn
- 1997-03-18 CA CA002247451A patent/CA2247451C/en not_active Expired - Fee Related
- 1997-03-18 WO PCT/JP1997/000852 patent/WO1997034869A1/ja active IP Right Grant
- 1997-03-18 NZ NZ331466A patent/NZ331466A/en not_active IP Right Cessation
- 1997-03-18 KR KR10-1998-0707382A patent/KR100485642B1/ko not_active IP Right Cessation
- 1997-03-18 CN CNB971931518A patent/CN1211361C/zh not_active Expired - Fee Related
- 1997-03-18 JP JP53335197A patent/JP3995716B2/ja not_active Expired - Fee Related
- 1997-03-18 AU AU19423/97A patent/AU723930B2/en not_active Ceased
- 1997-03-18 US US09/125,522 patent/US6121309A/en not_active Expired - Fee Related
- 1997-03-18 HU HU9902645A patent/HUP9902645A3/hu unknown
- 1997-03-18 CN CNB2004100420998A patent/CN1255396C/zh not_active Expired - Fee Related
-
1998
- 1998-09-17 NO NO19984331A patent/NO312759B1/no not_active IP Right Cessation
-
1999
- 1999-09-22 US US09/400,980 patent/US6110959A/en not_active Expired - Fee Related
-
2000
- 2000-07-21 US US09/621,889 patent/US6358995B1/en not_active Expired - Fee Related
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS4983725A (ja) * | 1972-11-28 | 1974-08-12 | ||
JPS49112926A (ja) * | 1973-02-09 | 1974-10-28 | ||
US4129568A (en) * | 1977-05-12 | 1978-12-12 | Monsanto Company | 2-[3-Aryl-2-isoxazolin-5-yl]benzoates |
US4135910A (en) * | 1977-05-12 | 1979-01-23 | Monsanto Company | Oxadiazol-3-yl-benzoates as plant growth regulants |
US4139366A (en) * | 1977-05-12 | 1979-02-13 | Monsanto Company | 2-[5-aryl-2-isoxazolin-3-yl]benzoates and use as herbicides |
US4166732A (en) * | 1977-05-12 | 1979-09-04 | Monsanto Company | Oxadiazol-5-yl-benzoates |
JPS6185360A (ja) * | 1984-09-19 | 1986-04-30 | サントル・アンテルナシヨナル・ド・ルシエルシユ・デルマトロジツク・セ.イ.エール.デ | 複素環レチノイド |
JPH06501948A (ja) * | 1990-10-09 | 1994-03-03 | アラーガン、インコーポレイテッド | レチノイド様活性を有するクロマンおよびチオクロマン |
JPH06502178A (ja) * | 1990-12-31 | 1994-03-10 | 藤沢薬品工業株式会社 | イミダゾトリアジン誘導体 |
WO1997002244A1 (fr) * | 1995-06-30 | 1997-01-23 | Eisai Co., Ltd. | Derives d'acides carboxyliques heterocycliques et medicaments les contenant |
Non-Patent Citations (8)
Title |
---|
CHEMICAL ABSTRACTS, 100, Abstract No. 87266; & SU,A,1 051 083. * |
CHEMICAL ABSTRACTS, 89, Abstract No. 129303; & BULL. CHEM. SOC. JPN., 51(5), (1978), pages 1473-6. * |
J. HETEROCYCL. CHEM., 19(4), (1982), HOWE ROBERT K. et al., pages 721-6. * |
J. INST. CHEM., (India), 49(6), (1977), BANERJEE M. et al., pages 291-3. * |
KHIM. GETEROTSKL. SOEDIN., (9), (1986), KRASOVITSKII B.M. et al., pages 1261-4. * |
LIEBIGS ANN. CHEM., (11), (1983), BOBERG FRIEDRICH et al., pages 2029-33. * |
PESTIC. SCI., 6(5), (1975), GEISSLER ART E. et al., pages 441-50. * |
See also references of EP0889032A4 * |
Cited By (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0930075A4 (en) * | 1996-10-03 | 2001-03-14 | Eisai Co Ltd | METHODS OF PREVENTING, INHIBITING OR TREATING REPLACEMENT REACTIONS IN THE GRAFT REACTION AGAINST HOST AND ORGAN TRANSPLANTATIONS |
JPH10158192A (ja) * | 1996-10-03 | 1998-06-16 | Eisai Co Ltd | 移植片対宿主疾患(gvhd)の治療および臓器移植時の移植片拒絶反応抑制のための医薬組成物 |
EP0930075A1 (en) * | 1996-10-03 | 1999-07-21 | Eisai Co., Ltd. | Methods for preventing, inhibiting or treating graft rejection reactions in graft-versus-host disease (gvhd) and organ transplantation |
US6258811B1 (en) | 1996-10-03 | 2001-07-10 | Eisai Co., Ltd. | Methods for preventing, inhibiting or treating graft rejection reactions in graft-versus-host disease (GVHD) and organ transplantation |
WO1998055454A2 (en) * | 1997-06-05 | 1998-12-10 | Takeda Chemical Industries, Ltd. | Benzofurans and benzothophenes as suppressors of neurodegeneration |
WO1998055454A3 (en) * | 1997-06-05 | 1999-03-04 | Takeda Chemical Industries Ltd | Benzofurans and benzothophenes as suppressors of neurodegeneration |
US7008950B1 (en) | 1997-06-05 | 2006-03-07 | Takeda Chemical Industries, Ltd. | Benzofurans as suppressors of neurodegeneration |
US6355669B1 (en) * | 1997-10-22 | 2002-03-12 | Eisai Co., Ltd. | Retinoic acid agonists as preventive and therapeutic agents for nephritis |
WO1999020309A1 (fr) * | 1997-10-22 | 1999-04-29 | Eisai Co., Ltd. | Agonistes de l'acide retinoique, agents preventifs et therapeutiques des nephrites |
WO1999049838A1 (fr) * | 1998-03-31 | 1999-10-07 | Galderma Research & Development, S.N.C. | Utilisation des inhibiteurs de l'activite de l'acide retinoique pour retarder la chute des cheveux |
FR2776511A1 (fr) * | 1998-03-31 | 1999-10-01 | Cird Galderma | Utilisation dans ou pour la preparation d'une composition d'au moins un inhibiteur de l'activite de l'acide retinoique |
US6869959B1 (en) | 1999-04-28 | 2005-03-22 | Institute Of Medicinal Molecular Design Inc. | Heterocyclic carboxylic acid derivatives |
JP2003531180A (ja) * | 2000-04-20 | 2003-10-21 | アラーガン、インコーポレイテッド | 軟骨および骨の疾患の治療におけるレチノイド受容体拮抗薬または作用薬の使用 |
JP2003081832A (ja) * | 2001-06-26 | 2003-03-19 | Takeda Chem Ind Ltd | レチノイド関連受容体機能調節剤 |
US7223791B2 (en) | 2001-06-26 | 2007-05-29 | Takeda Pharmaceutical Company Limited | Function regulator for retinoid relative receptor |
JP2008515985A (ja) * | 2004-10-13 | 2008-05-15 | ピーティーシー セラピューティクス,インコーポレーテッド | ナンセンス抑制の化合物とその使用方法 |
US9611230B2 (en) | 2004-10-13 | 2017-04-04 | Ptc Therapeutics, Inc. | 1,3,4-oxadiazole benzoic acid compounds and their use for nonsense suppression and the treatment of disease |
JP2012524715A (ja) * | 2009-04-02 | 2012-10-18 | メルク セローノ ソシエテ アノニム | ジヒドロオロテート脱水素酵素阻害剤 |
KR20170097125A (ko) * | 2014-12-17 | 2017-08-25 | 킹즈 컬리지 런던 | 레티노산 수용체 베타 (RARβ) 작동제로서 바이사이클로헤테로아릴-헤테로아릴-벤조산 화합물 |
JP2017537967A (ja) * | 2014-12-17 | 2017-12-21 | キングス カレッジ ロンドン | レチノイン酸受容体ベータ(RARβ)アゴニストとしてのビシクロヘテロアリール−ヘテロアリール−安息香酸化合物 |
KR102526625B1 (ko) | 2014-12-17 | 2023-04-27 | 킹즈 컬리지 런던 | 레티노산 수용체 베타 (RARβ) 작동제로서 바이사이클로헤테로아릴-헤테로아릴-벤조산 화합물 |
JP2019522650A (ja) * | 2016-06-22 | 2019-08-15 | キングス カレッジ ロンドン | 4−(5−(4,7−ジメチルベンゾフラン−2−イル)−1,2,4−オキサジアゾール−3−イル)安息香酸の結晶形態及びそれらの調製方法 |
Also Published As
Publication number | Publication date |
---|---|
HUP9902645A2 (hu) | 1999-11-29 |
NO984331L (no) | 1998-11-11 |
NO312759B1 (no) | 2002-07-01 |
CN1211361C (zh) | 2005-07-20 |
US6110959A (en) | 2000-08-29 |
CA2247451A1 (en) | 1997-09-04 |
NO984331D0 (no) | 1998-09-17 |
CN1255396C (zh) | 2006-05-10 |
AU1942397A (en) | 1997-10-10 |
HUP9902645A3 (en) | 1999-12-28 |
US6358995B1 (en) | 2002-03-19 |
KR20000064666A (ko) | 2000-11-06 |
EP0889032A1 (en) | 1999-01-07 |
NZ331466A (en) | 2000-06-23 |
KR100485642B1 (ko) | 2005-09-30 |
AU723930B2 (en) | 2000-09-07 |
EP0889032A4 (en) | 2000-01-05 |
US6121309A (en) | 2000-09-19 |
CA2247451C (en) | 2006-01-03 |
JP3995716B2 (ja) | 2007-10-24 |
CN1214042A (zh) | 1999-04-14 |
CN1548428A (zh) | 2004-11-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1997034869A1 (fr) | Derives de l'acide carboxylique a cycles fusionnes | |
EP2928471B1 (en) | Histone demethylase inhibitors | |
CN104822687B (zh) | 抗纤维化吡啶酮类 | |
WO1999020309A1 (fr) | Agonistes de l'acide retinoique, agents preventifs et therapeutiques des nephrites | |
Kamal et al. | Combretastatin linked 1, 3, 4-oxadiazole conjugates as a Potent Tubulin Polymerization inhibitors | |
JP2000509719A (ja) | 置換されたアザビシクロ化合物、ならびにtnfおよびサイクリックampホスホジエステラーゼ産生の阻害剤としてのそれらの使用 | |
BRPI0614544A2 (pt) | derivados de benzoquinazolina e uso dos mesmos no tratamento de doenças ósseas | |
JP2003501464A (ja) | シクロオキシゲナーゼ−2の阻害剤としての1−(4−スルファミルアリール)−3−置換−5−アリール−2−ピラゾリン | |
WO2001032621A1 (fr) | Nouveaux derives d'indole, et medicaments contenant lesdits derives comme principe actif | |
CA2460942A1 (en) | Substituted pyrazolyl compounds for the treatment of inflammation | |
WO1996013478A1 (fr) | Derive d'acide carboxylique mono ou polyenique | |
JP2002514639A (ja) | ナフト[2,3−b]ヘテロアリー−4−イル誘導体 | |
JP2001517654A (ja) | Cox−2のインヒビターとして有用なジアリールピリジンの製造方法 | |
Arfaie et al. | Design, synthesis and biological evaluation of new (E)-and (Z)-1, 2, 3-triaryl-2-propen-1-ones as selective COX-2 inhibitors | |
JP2009504575A (ja) | 新規の置換された1,2,3,−トリアゾリルメチル−ベンゾチオフェン又は−インドール並びにロイコトリエン生合成阻害剤としてのそれらの使用 | |
AU2018253069A1 (en) | Liver X receptors (LXR) modulators | |
JP5847710B2 (ja) | 低酸素模倣体としての化合物、およびその組成物、およびその使用 | |
US6258811B1 (en) | Methods for preventing, inhibiting or treating graft rejection reactions in graft-versus-host disease (GVHD) and organ transplantation | |
WO1990005132A1 (en) | Substituted allylamine derivatives, process for their preparation and their use | |
WO2019144765A1 (zh) | 芳香杂环取代烯烃化合物、其制备方法、药物组合物和应用 | |
US6121271A (en) | Naphtho[2,3-B]heteroar-4-yl derivatives | |
EP1701942B1 (en) | Non-nucleotide reverse transcriptase inhibitors | |
JP2004043458A (ja) | 4−アリール−5−ヒドロキシイソキノリン誘導体およびその製造法 | |
RU2195448C2 (ru) | Производное карбоновой кислоты с конденсированными кольцами и фармацевтическая композиция на его основе | |
CN110684020B (zh) | 2-胺基嘧啶类衍生物、其制备方法及其在医药上的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 97193151.8 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA CN HU JP KR MX NO NZ RU US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 331466 Country of ref document: NZ Ref document number: 09125522 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1997907344 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2247451 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/1998/007382 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1019980707382 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 1997907344 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: CA |
|
WWP | Wipo information: published in national office |
Ref document number: 1019980707382 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 1019980707382 Country of ref document: KR |